# MAIN technical verification — October 26, 2026

The technical acceptance rule is independent of SCIENCE investigation completion and OUTCOME predictive validation. All ten technical prerequisite components retain their own acceptance evidence requirements. Correcting the rule promotes no gate and establishes no FDA probability.

## Read-only production observations

Completed at 2026-10-26T23:06:37+00:00. Command: `python3 scripts/check_system_status_production.py`.

- Production `/installation-audit` returned HTTP 200 with all 15 sections and both protected-evidence panel controls.
- Anonymous `/api/assessments`, `/api/hop/readiness`, and the exact-NCT `/api/phase3-registry` lookup each returned JSON HTTP 401 with only the expected authentication error.
- The production Phase 3 explorer returned HTTP 200.
- The public dated research CSV matched the committed source byte for byte: 741 unique NCT IDs, 130 tickers, SHA256 `a426ac6c01726a2c3a9916698e50f3cc87b0e6230260068231c88f1b4a30a143`. This proves served-file consistency, not Pipeline qualification.

## Engineering checks

TypeScript, all 385 frontend tests, and the Next.js production build passed. The production-rendered page contains the corrected independent technical scope, 0/10 accepted prerequisite components, and the unchanged 1/31 verified daily-gate baseline. Tests verify that missing technical runtime/backup evidence still blocks acceptance, successful research cannot clear it, and unverified research cannot block a technically accepted installation. Legacy v1 policy deltas are withheld.

## Remaining boundary

This browser reached the normal setup-password sign-in screen without a signed-in dashboard session. Authenticated frontend-to-backend operation, live restrictions/list interactions, private source health and a production restore remain unverified by this check. No authentication bypass, restrictions/preset edits, scan, notification, order, trade, or production-data mutation was performed by the public smoke check. The existing SEC/financial and regulatory source gaps remain explicit.
